<DOC>
	<DOCNO>NCT02811250</DOCNO>
	<brief_summary>Stereotactic radiotherapy technique allow delivery high dose radiation fraction ( 3-6 ) great precision . It thus allow `` tumor ablation '' optimal preservation healthy tissue . Initially developed small-sized ( &lt; 5 cm ) lung cancer technique give result close even equivalent surgery . Stereotactic radiotherapy brain metastasis renal cancer show high dos radiation allow local control 90 98 % case . A study conduct Sweden ( Wersall et al . ) underline interest develop stereotactic radiotherapy primary renal tumor . In Cleveland ( USA ) two phase I study already underway . The investigator propose develop phase I study tumor le 4 cm . As found lung cancer , stereotactic radiotherapy provide non-invasive , painless rapid ( 4 5 fraction ) method treatment renal cancer high rate local control . The primary objective define maximal tolerate dose one fraction stereotactic mode renal tumor ≤ 4 cm length use four-step dose increase : - Step 1 : 4 x 8 Gy . - Step 2 : 5 x 8 Gy . - Step 3 : 4 x 10 Gy . - Step 4 : 4 x 12 Gy . The patient follow treatment evaluation acute toxicity session , 15 day , 6 week , 3 month , 9 month , 12 month , every 6 month total duration 5 year treatment .</brief_summary>
	<brief_title>Stereotactic Radiotherapy Renal Cancers</brief_title>
	<detailed_description />
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<criteria>Patient age 75 year operable renal tumor patient inoperable renal tumor irrespective age , patient metastatic renal tumor indication nephrectomy . Histologicallyconfirmed Renal carcinoma less equal 4 cm Tumor visible measureable abdominal scanner and/or MRI ( Magnetic Resonance Imaging ) Karnofsky performance status ≥ 60 % Patient one kidney renal cancer Patient able cooperate treatment Previous history abdominal radiation therapy Tumor infiltrate renal pelvis Polycystic kidney disease Previous history intestinal inflammatory disease ulcerative colitis Crohn 's disease Renal insufficiency ( creatinine clearance &lt; 30 ml/mm evaluate DTPA ( diethylenetriamine pentaacetic acid ) scintigraphy ) Uncontrolled hypertension ( SBP ( systolic blood pressure ) 160 mmHg DBP ( diastolic blood pressure ) 100 mmHg antihypertensive treatment ) Non primary lesion ( benign lesion angiomyolipoma , renal metastasis , … ) Antineoplastic and/or antiangiogenic treatment month precede radiotherapy Progressive cancer renal cancer time inclusion exception situ cervical carcinoma , basal cell carcinoma skin , nonmetastatic prostate cancer control without hormone therapy Participation another ongoing study may interfere present study</criteria>
	<gender>All</gender>
	<minimum_age>75 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Renal cancer</keyword>
	<keyword>Stereotactic radiotherapy</keyword>
</DOC>